Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

Thu, 28 May 2026 09:17:00 -0400

CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers

Watch the “What This Means” video here

TAMPA, Fla. and LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that its CEO participated in a Virtual Investor “What This Means” interview focused on the Company’s recently accepted abstract at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

Thu, 28 May 2026 09:17:00 -0400

CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers

Watch the “What This Means” video here

Akari Therapeutics reports preclinical data on cancer drug combination

Thu, 21 May 2026 17:01:20 -0400

Akari Therapeutics Plc (NASDAQ: AKTX) announced preclinical data showing synergistic activity between its experimental cancer drug AKTX-101 and KRAS inhibition in pancreatic cancer models with KRAS mutations.

The data, featured in an abstract for the American Society of Clinical Oncology Annual Meeting 2026, evaluated AKTX-101 in combination with adagrasib, a KRAS inhibitor, across pancreatic cancer cell lines harboring KRAS G12D and KRAS G12C mutations. The combination demonstrated synergistic cell killing in these KRAS mutant cell lines.

According to the company's statement, this synergistic inhibition was not observed with comparator topoisomerase I-targeting TROP2 antibody drug conjugates, which instead exhibited antagonism when paired with

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

Thu, 21 May 2026 17:01:00 -0400

An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer models

Data supports the broader applicability of targeting RNA splicing to attack difficult-to-treat KRAS-driven cancers

Findings featured in ASCO 2026 online abstract further differentiate AKTX-101 from TROP2 ADCs utilizing Topoisomerase I inhibitor payloads

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

Thu, 21 May 2026 17:01:00 -0400

Findings featured in ASCO 2026 online abstract further differentiate AKTX-101 from TROP2 ADCs utilizing Topoisomerase I inhibitor payloads

Akari Therapeutics raises $5.5 million in private placement

Thu, 21 May 2026 08:30:17 -0400

Akari Therapeutics Plc (NASDAQ: AKTX) announced the pricing of a private placement financing expected to raise approximately $5.5 million in gross proceeds. The biotechnology company develops antibody drug conjugates with RNA splicing modulator payloads for oncology applications.

The company issued 1,470,588 American Depository Shares at $3.74 per share, along with Series H, I and J warrants. The warrants require shareholder approval and are exercisable for 1,470,588 ADSs each at $3.74 per share. Series H warrants have an 18-month term, while Series I and J warrants have 60-month terms.

Akari plans to use the net proceeds for working capital and general corporate purposes,

Akari Therapeutics Announces $5.5 Million Private Placement Offering

Thu, 21 May 2026 08:30:00 -0400

TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $5.5 million in gross proceeds. With these funds the Company will focus on advancing its lead ADC program utilizing its unique RNA splicing modulator payload, AKTX-101, toward a first-in-human Phase 1 clinical trial.

“This financing reflects deep conviction from our long-term strategic investors

Akari Therapeutics Announces $5.5 Million Private Placement Offering

Thu, 21 May 2026 08:30:00 -0400

“This financing reflects deep conviction from our long-term strategic investors

Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase

Mon, 18 May 2026 09:05:00 -0400